Search results
Results from the WOW.Com Content Network
Compared to THC, which is a partial agonist at CB 1 receptors, JWH-018, and many synthetic cannabinoids, are full agonists. JWH-018 may cause intense anxiety, agitation, and in rare cases, has been assumed to have been the cause of seizures and convulsions. JWH-018 and analogs of it may present serious dangers to the user when used to excess. [22]
XLR-11 (5"-fluoro-UR-144 or 5F-UR-144) is a drug that acts as a potent agonist for the cannabinoid receptors CB 1 and CB 2 with EC 50 values of 98 nM and 83 nM ...
AB-CHMINACA is an indazole-based synthetic cannabinoid.It is a potent agonist of the CB 1 receptor (K i = 0.78 nM) and CB 2 receptor (K i = 0.45 nM) and fully substitutes for Δ 9-THC in rat discrimination studies, while being 16x more potent.
5F-CUMYL-PINACA (also known as SGT-25 and sometimes sold in e-cigarette form as C-Liquid) [1] is an indazole-3-carboxamide based synthetic cannabinoid. [2] 5F-CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with the original patent claiming approximately 4x selectivity for CB 1, having an EC 50 of <0.1 nM for human CB 1 receptors and 0.37 nM for human CB 2 receptors. [3]
AM-679 (part of the AM cannabinoid series) is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a K i of 13.5 nM at CB 1 and 49.5 nM at CB 2. [1]
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. [3] It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University .
AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA [3]) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with K i values of 10.04 nM at CB 1 and 0.786 nM at CB 2 and EC 50 values of 0.5433 nM at CB 1 and 0.1278 nM at CB 2, [4] and has been sold online as a designer drug.
ADB-5'Br-BUTINACA (ADB-B-5Br-INACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug, [1] first detected in Philadelphia in the US in May 2022, [2] and subsequently found in South Korea, [3] Portugal and Sweden. [4]